Newlink Genetics reported -7497000 in Operating Profit for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Bristol Myers Squibb BMY:US $ 1996M 281M
Capricor Therapeutics CAPR:US $ -4.32M 0.45M
Celldex Therapeutics CLDX:US $ -20.82M 7.38M
Eli Lilly And LLY:US $ 1476M 72.6M
Idera Pharmaceuticals IDRA:US $ -5.97M 1.59M
Intrexon XON:US $ -25.47M 9.8M
Merk MRK:US $ 4826M 3212M
Nektar Therapeutics NKTR:US $ -113.6M 3.39M
Newlink Genetics NLNK:US -7497000 1.17M
Pfizer PFE:US $ 7647M 1733M
Prothena PRTA:US 109.23M 81.28M
Sarepta Therapeutics SRPT:US $ -38.95M 128.63M
Vascular Biogenics VBLT:US -6513000 1.51M
YTE INCY:US $ 235.41M 94.57M